Training & Education

Mammography topics

Future of Breast Cancer Screening with Digital Breast Tomosynthesis

Full-field digital mammography (FFDM) is currently the gold standard in breast cancer screening.1 It delivers high-resolution images of the breast, but it has a limitation that’s inherent to the acquisition method: tissue superimposition. Among this challenge in breast screening are interval cancers and until now 20-25% of interval cancers are classified as being missed as false negatives2.
To resolve this issue, in recent years digital breast tomosynthesis (DBT) has been introduced in clinical practice and in the near future it may replace digital mammography as the breast screening modality of choice.

Which breast imaging technologies challenge digital mammography in breast screening: The latest results of clinical trials were presented at a Breast Care Day symposium at the ECR 2022. The studies were analyzed in terms of their effectiveness in population screening. A special focus was put on the detection of interval cancers breast as a good performance indicator for the efficiency of a screening method3

How did the pandemic harm breast screening programs and what should a return strategy look like?

In this keynote talk Prof. Dr. Federica Pediconi (Sapienza University of Rome, Italy) reviews the literature regarding the effect of the pandemic on screening programs and breast cancer mortality. She analyzes how the pandemic has modified the approach to patient care, current restart strategies, and possible directions for the future. (ECR, July 2022)

Interval cancers in screening with breast tomosynthesis: Results and cases from the Malmö trial 

In this online seminar, Dr. Kristin Johnson and Prof. Dr. Sophia Zackrisson (Malmö, Sweden) discuss results and exemplary cases from the Malmö trial with the audience. (EUSOBI ASM, Oct. 2021) 

Subscription Button Icon

Keep up to date on the latest trends in healthcare. Read about current developments, new products and upcoming events.